Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine Linn

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trialChristine Desmedt, Ha-Linh Nguyen, François Richard, et al.
Breast (Edinburgh, Scotland)|August 23, 2025
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectivesLeonor Matos, Mette van Ramshorst, Volkmar Müller, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2014
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trialDuveken B Y Fontein, Ayoub Charehbili, Johan W R Nortier, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
The Journal of Pathology|May 25, 2023
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studiesGregory Verghese, Mengyuan Li, Fangfang Liu, et al.
Molecular Oncology|May 26, 2015
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialTesa M Severson, Justine Peeters, Ian Majewski, et al.
Cancer Treatment Reviews|May 22, 2026
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposalAldo Caltavituro, Roberto Buonaiuto, Alessandra Longobardi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2020
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapyLeonora de Boo, Ashley Cimino-Mathews, Yoni Lubeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast CancerMarleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trialChristine Desmedt, Ha-Linh Nguyen, François Richard, et al.
Breast (Edinburgh, Scotland)|August 23, 2025
Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectivesLeonor Matos, Mette van Ramshorst, Volkmar Müller, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2014
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trialDuveken B Y Fontein, Ayoub Charehbili, Johan W R Nortier, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
The Journal of Pathology|May 25, 2023
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studiesGregory Verghese, Mengyuan Li, Fangfang Liu, et al.
Molecular Oncology|May 26, 2015
BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialTesa M Severson, Justine Peeters, Ian Majewski, et al.
Cancer Treatment Reviews|May 22, 2026
Central nervous system and leptomeningeal metastases in patients with HER2-positive breast cancer: A comprehensive review and therapeutic algorithm proposalAldo Caltavituro, Roberto Buonaiuto, Alessandra Longobardi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2020
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapyLeonora de Boo, Ashley Cimino-Mathews, Yoni Lubeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast CancerMarleen Kok, Robbert-Jan Gielen, Sylvia Adams, et al.
Pageof 5